Bronchial asthma (BA) is one of the socially significant diseases, characterized by a high frequency of seeking medical help and mortality. The most important parameter in studies of drug consumption is the study of the structure of their use, which includes the volume of use and a number of qualitative characteristics of the use of drugs of the group being studied. Modern approaches to pharmacotherapy of asthma also include the use of drugs in combinations; such drug therapy makes it possible to control the course of asthma, which affects morbidity, mortality, quality of life and the quality of provision of pharmaceutical and medical care to the population. Aim. Study of the frequency and structure of prescription of drugs used in the pharmacotherapy of bronchial asthma. Matherials and Methods. During a retrospective pharmacoepidemiological study, 500 individual registration records of patients with bronchial asthma who were hospitalized for the period 2020 - 2023 were analyzed. in healthcare organizations of the Ministry of Health of the Kyrgyz Republic. Results. When analyzing the number of prescribed medications, it was found that in the pharmacotherapy of 500 patients with bronchial asthma in different combinations, 11 names of medications under international nonproprietary names and 26 medications under trade names were used, while the total number of prescribed medications per patient varied from 1 to 5 types of drugs in 62 different combinations. Of the combinations of salbutamol with drugs from other pharmacological groups, the leading ones were the simultaneous administration of 3 drugs: Salbutamol + Ambroxol + Theophylline; for beclomethasone, a combination of 5 drugs: Beclomethasone + Salbutamol + Ambroxol + Salbutamol + Theophylline; for salmeterol, a combination of 5 drugs: Salmeterol + Fluticacone, Salbutamol, Acetylcysteine, Salbutamol. Conclusions. A study of the structure of medications used in the hospital in the treatment of patients with bronchial asthma made it possible to establish that the largest share of drug prescriptions was for the treatment regimen Beclomethasone + Salbutamol + Ambroxol + Salbutamol + Theophylline, which was used in the treatment of 67 patients. The regimen Salbutamol + Ambroxol + Theophylline was used in the treatment of 62 patients and the prevailing treatment regimens were Salmeterol + Fluticacone, Salbutamol, Ambroxol, Theophylline and Salmeterol + Fluticacone, Salbutamol, Ambroxol, Salbutamol, Theophylline, each of which was used in the treatment of 28 patients.